Green Cross Corp (006280) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.094x

Based on the latest financial reports, Green Cross Corp (006280) has a cash flow conversion efficiency ratio of 0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩139.65 Billion ≈ $94.64 Million USD) by net assets (₩1.49 Trillion ≈ $1.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 006280 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Green Cross Corp - Cash Flow Conversion Efficiency Trend (2004–2024)

This chart illustrates how Green Cross Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Green Cross Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Green Cross Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
JinkoSolar Holding Co. Ltd
F:ZJS1
0.075x
Jefferson Capital, Inc. Common Stock
NASDAQ:JCAP
0.144x
Shijiazhuang Tonhe Electronics Technologies Co Ltd
SHE:300491
0.075x
Beijing Watertek Information Technology Co Ltd
SHE:300324
0.004x
Glotech Industrial
TWO:5475
-0.015x
Aedas Homes SL
MC:AEDAS
0.215x
UP FINT. HLDG (SP.ADR) A
F:1M5
N/A
EPIC Suisse AG
SW:EPIC
0.034x

Annual Cash Flow Conversion Efficiency for Green Cross Corp (2004–2024)

The table below shows the annual cash flow conversion efficiency of Green Cross Corp from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see Green Cross Corp (006280) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩1.48 Trillion
≈ $1.00 Billion
₩-53.46 Billion
≈ $-36.23 Million
-0.036x -915.64%
2023-12-31 ₩1.54 Trillion
≈ $1.04 Billion
₩-5.47 Billion
≈ $-3.71 Million
-0.004x -104.67%
2022-12-31 ₩1.57 Trillion
≈ $1.06 Billion
₩119.15 Billion
≈ $80.75 Million
0.076x -9.46%
2021-12-31 ₩1.50 Trillion
≈ $1.02 Billion
₩125.98 Billion
≈ $85.37 Million
0.084x +196.39%
2020-12-31 ₩1.27 Trillion
≈ $860.19 Million
₩35.97 Billion
≈ $24.38 Million
0.028x -16.71%
2019-12-31 ₩1.18 Trillion
≈ $802.43 Million
₩40.29 Billion
≈ $27.30 Million
0.034x +165.94%
2018-12-31 ₩1.13 Trillion
≈ $763.21 Million
₩14.41 Billion
≈ $9.77 Million
0.013x -75.49%
2017-12-31 ₩1.11 Trillion
≈ $751.36 Million
₩57.88 Billion
≈ $39.22 Million
0.052x +3273.10%
2016-12-31 ₩1.06 Trillion
≈ $717.68 Million
₩-1.74 Billion
≈ $-1.18 Million
-0.002x -103.63%
2015-12-31 ₩997.70 Billion
≈ $676.13 Million
₩45.24 Billion
≈ $30.66 Million
0.045x -26.45%
2014-12-31 ₩920.63 Billion
≈ $623.90 Million
₩56.76 Billion
≈ $38.47 Million
0.062x +74.32%
2013-12-31 ₩839.41 Billion
≈ $568.86 Million
₩29.69 Billion
≈ $20.12 Million
0.035x -52.25%
2012-12-31 ₩685.23 Billion
≈ $464.37 Million
₩50.76 Billion
≈ $34.40 Million
0.074x -14.89%
2011-12-31 ₩630.28 Billion
≈ $427.13 Million
₩54.86 Billion
≈ $37.17 Million
0.087x -44.13%
2010-12-31 ₩542.23 Billion
≈ $367.46 Million
₩84.47 Billion
≈ $57.25 Million
0.156x +6.04%
2006-12-31 ₩185.98 Billion
≈ $126.03 Million
₩27.32 Billion
≈ $18.52 Million
0.147x -8.02%
2005-12-31 ₩145.70 Billion
≈ $98.74 Million
₩23.27 Billion
≈ $15.77 Million
0.160x +6.53%
2004-12-31 ₩108.95 Billion
≈ $73.83 Million
₩16.34 Billion
≈ $11.07 Million
0.150x --

About Green Cross Corp

KO:006280 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$1.01 Billion
₩1.49 Trillion KRW
Market Cap Rank
#9024 Global
#245 in Korea
Share Price
₩130600.00
Change (1 day)
-0.38%
52-Week Range
₩118700.00 - ₩180300.00
All Time High
₩493171.17
About

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more